174 related articles for article (PubMed ID: 22298604)
1. Serum potassium influencing interacting drugs: risk-modifying strategies also needed at discontinuation.
Uijtendaal EV; Zwart-van Rijkom JE; van Solinge WW; Egberts TC
Ann Pharmacother; 2012 Feb; 46(2):176-82. PubMed ID: 22298604
[TBL] [Abstract][Full Text] [Related]
2. Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.
Uijtendaal EV; Zwart-van Rijkom JE; van Solinge WW; Egberts TC
Eur J Clin Pharmacol; 2011 Sep; 67(9):933-40. PubMed ID: 21424384
[TBL] [Abstract][Full Text] [Related]
3. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals.
Noize P; Bagheri H; Durrieu G; Haramburu F; Moore N; Giraud P; Galinier M; Pourrat J; Montastruc JL
Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):747-53. PubMed ID: 21438068
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of a modification of diet in renal disease equation-based potassium replacement protocol.
Chapman SA; Kaufenberg AJ; Anderson P; Khokhar A; Schrock CG
Ann Pharmacother; 2009 Mar; 43(3):436-43. PubMed ID: 19240261
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment.
Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E
Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481
[TBL] [Abstract][Full Text] [Related]
7. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with spironolactone in pediatrics.
Buck ML
Ann Pharmacother; 2005 May; 39(5):823-8. PubMed ID: 15811903
[TBL] [Abstract][Full Text] [Related]
9. Potassium-lowering effect of albuterol for hyperkalemia in renal failure.
Montoliu J; Lens XM; Revert L
Arch Intern Med; 1987 Apr; 147(4):713-7. PubMed ID: 3827459
[TBL] [Abstract][Full Text] [Related]
10. Serum Potassium Levels at Hospital Discharge and One-Year Mortality among Hospitalized Patients.
Thongprayoon C; Cheungpasitporn W; Thirunavukkarasu S; Petnak T; Chewcharat A; Bathini T; Vallabhajosyula S; Mao MA; Erickson SB
Medicina (Kaunas); 2020 May; 56(5):. PubMed ID: 32423140
[No Abstract] [Full Text] [Related]
11. Hypokalemia in a pediatric intensive care unit.
Singhi S; Marudkar A
Indian Pediatr; 1996 Jan; 33(1):9-14. PubMed ID: 8772944
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
Burnakis TG; Mioduch HJ
Arch Intern Med; 1984 Dec; 144(12):2371-2. PubMed ID: 6391404
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
[TBL] [Abstract][Full Text] [Related]
14. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals.
Ramírez E; Rossignoli T; Campos AJ; Muñoz R; Zegarra C; Tong H; Medrano N; Borobia AM; Carcas AJ; Frías J
Eur J Clin Pharmacol; 2013 Jan; 69(1):97-110. PubMed ID: 22648277
[TBL] [Abstract][Full Text] [Related]
16. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
Shah KB; Rao K; Sawyer R; Gottlieb SS
J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
[TBL] [Abstract][Full Text] [Related]
17. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study.
Krijthe BP; Heeringa J; Kors JA; Hofman A; Franco OH; Witteman JC; Stricker BH
Int J Cardiol; 2013 Oct; 168(6):5411-5. PubMed ID: 24012173
[TBL] [Abstract][Full Text] [Related]
18. Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients.
Mahajan SK; Mangla M; Kishore K
J Assoc Physicians India; 2001 Nov; 49():1082-5. PubMed ID: 11868861
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Tamirisa KP; Aaronson KD; Koelling TM
Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
[TBL] [Abstract][Full Text] [Related]
20. Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions.
Henz S; Maeder MT; Huber S; Schmid M; Loher M; Fehr T
Nephrol Dial Transplant; 2008 Dec; 23(12):3939-45. PubMed ID: 18614817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
